OREX up +25.19% percent Today $OREX High is at 4.7
Post# of 68
Posted On: 11/10/2014 2:53:12 PM
OREX up +25.19% percent Today $OREX High is at 4.79 and the Low 4.04 with current volume of 4,685,142.
Recent News posted below.
Orexigen Therapeutics OREX other info.
http://investorshangout.com/Orexigen-Therapeu...REX-55007/
OREX Orexigen Therapeutics Recent Headline News
Arena And Vivus Investors Need To Watch Orexigen
Spencer Osborne - at Seeking Alpha - 1 hr 28 mins ago
OREX: 5.08 (+1.23), VVUS: 3.23 (-0.10), ARNA: 4.34 (+0.08)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - 1 hr 52 mins ago
UCP: 11.82 (-1.97), JRJC: 6.21 (+0.70), NAVB: 1.03 (-0.19), SANW: 3.76 (+0.68), PLPM: 1.63 (+0.26), RYN: 28.62 (-5.28), INFU: 3.02 (-0.47), LIOX: 5.49 (+0.75), DY: 27.75 (-3.12), MTZ: 25.31 (-3.32), CGIX: 6.92 (+0.92), MUX: 1.25 (-0.16), OREX: 5.08 (+1.23), URRE: 2.54 (+0.60), ACHN: 12.54 (+2.43), REN: 2.83 (-0.78), MPO: 3.33 (+0.22), AKBA: 9.28 (-1.42), TRX: 1.02 (-0.20), PLNR: 7.53 (+1.13)
Stock to Watch: Orexigen Therapeutics Up 19.5% (OREX)
Comtex SmarTrend(R) - 2 hrs 25 mins ago
Orexigen Therapeutics (NASDAQ:OREX) is one of today's best performing low-priced stocks, up 19.5% to $4.60 on 1.1x average daily volume. Orexigen Therapeutics has traded 3.6 million shares thus far today, vs. average volume of 3.3 million shares per day. The stock has outperformed the Dow (19.5% to the Dow's 0.1%) and outperformed the S&P 500 (19.5% to the S&P's 0.3%) during today's trading.
OREX: 5.08 (+1.23)
Orexigen Therapeutics' (OREX) CEO Mike Narachi on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 10:51AM CST
OREX: 5.08 (+1.23)
Orexigen ups earnings by 161% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:16AM CST
OREX: 5.08 (+1.23)
Orexigen rises as weight loss drug review proceeds
AP - Mon Nov 10, 10:02AM CST
NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.
OREX: 5.08 (+1.23), VVUS: 3.23 (-0.10), ARNA: 4.34 (+0.08)
Orexigen Therapeutics (OREX) Stock Soars Today on Big Third Quarter Earnings Beat
at The Street - Mon Nov 10, 9:33AM CST
Orexigen Therapeutics (OREX) stock is skyrocketing this morning after the company posted higher than expected third quarter earnings.
OREX: 5.08 (+1.23)
Orexigen Beats The Street On Milestone Payments
Spencer Osborne - at Seeking Alpha - Mon Nov 10, 8:21AM CST
OREX: 5.08 (+1.23)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:14AM CST
PT: 1.63 (+0.11), GPRO: 76.08 (-2.98), OREX: 5.08 (+1.23), GOGO: 18.04 (+1.40), JRJC: 6.21 (+0.70), UEC: 1.87 (+0.15), ACHN: 12.54 (+2.43), ARQL: 1.16 (+0.10), CMCM: 20.50 (+0.30), IBIO: 1.24 (+0.08), DF: 16.31 (+1.89)
Orexigen Therapeutics (OREX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 7:25AM CST
OREX: 5.08 (+1.23)
Orexigen Therapeutics beats by $0.22, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:08AM CST
OREX: 5.08 (+1.23)
Orexigen Therapeutics Reports Results for the Third Quarter Ended September 30, 2014
PR Newswire - Mon Nov 10, 6:00AM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced results for the third quarter ended September 30, 2014.
OREX: 5.08 (+1.23)
Critical Alerts For Stratasys, Orexigen Therapeutics, YY, Workday and Hong Kong Television Network Released By InvestorsObserver
PR Newswire - Fri Nov 07, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for SSYS, OREX, YY, WDAY and HKTV.
OREX: 5.08 (+1.23), YY: 81.94 (+2.44), WDAY: 95.33 (+0.77), SSYS: 104.40 (+1.33), HKTV: 11.08 (+0.21)
Orexigen Therapeutics to Present at the Credit Suisse Healthcare Conference
PR Newswire - Thu Nov 06, 3:30PM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Credit Suisse Healthcare Conference in Phoenix. The presentation is scheduled for Tuesday, November 11th at 2:00 p.m. Mountain Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
OREX: 5.08 (+1.23)
Vivus Beats The Street On Milestone Payment For ED Drug
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:59AM CST
OREX: 5.08 (+1.23), VVUS: 3.23 (-0.10), ARNA: 4.34 (+0.08)
Orexigen Therapeutics to Host Third Quarter 2014 Financial Results Conference Call and Webcast
PR Newswire - Tue Nov 04, 3:15PM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) will announce financial results for the third quarter 2014, on Monday, November 10, 2014 before markets open. The announcement will be followed by a live webcast and conference call at 8:30 a.m. Eastern time (5:30 a.m. Pacific time).
OREX: 5.07 (+1.22)
Orexigen's Contrave Has Modest Start
Spencer Osborne - at Seeking Alpha - Mon Nov 03, 12:30PM CST
OREX: 5.07 (+1.22), ARNA: 4.34 (+0.08)
Orexigen Announces Contrave® (naltrexone HCI and bupropion HCI extended release) Data Presentations at the ObesityWeek Meeting in Boston
PR Newswire - Fri Oct 31, 7:30AM CDT
Orexigen Therapeutics (NASDAQ: OREX) today announced three Contrave® (naltrexone HCI and bupropion HCI) and two disease awareness abstracts have been accepted for poster presentations at the upcoming ObesityWeek meeting. This meeting will be held November 2-7, 2014 in Boston at the Boston Convention and Exposition Center.
OREX: 5.07 (+1.22)
Orexigen Therapeutics Has Substantial Upside For Bull Investors
L&F Capital Management - at Seeking Alpha - Wed Oct 29, 7:27AM CDT
OREX: 5.07 (+1.22)
Arena Skimps on Data Disclosure From Weight-Loss Combo Study
at The Street - Wed Oct 29, 6:30AM CDT
Arena Pharmaceuticals provided very little useful information Tuesday night about the Belviq-phentermine weight-loss combination.
OREX: 5.07 (+1.22), ARNA: 4.34 (+0.08)
Recent News posted below.
Orexigen Therapeutics OREX other info.
http://investorshangout.com/Orexigen-Therapeu...REX-55007/
OREX Orexigen Therapeutics Recent Headline News
Arena And Vivus Investors Need To Watch Orexigen
Spencer Osborne - at Seeking Alpha - 1 hr 28 mins ago
OREX: 5.08 (+1.23), VVUS: 3.23 (-0.10), ARNA: 4.34 (+0.08)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - 1 hr 52 mins ago
UCP: 11.82 (-1.97), JRJC: 6.21 (+0.70), NAVB: 1.03 (-0.19), SANW: 3.76 (+0.68), PLPM: 1.63 (+0.26), RYN: 28.62 (-5.28), INFU: 3.02 (-0.47), LIOX: 5.49 (+0.75), DY: 27.75 (-3.12), MTZ: 25.31 (-3.32), CGIX: 6.92 (+0.92), MUX: 1.25 (-0.16), OREX: 5.08 (+1.23), URRE: 2.54 (+0.60), ACHN: 12.54 (+2.43), REN: 2.83 (-0.78), MPO: 3.33 (+0.22), AKBA: 9.28 (-1.42), TRX: 1.02 (-0.20), PLNR: 7.53 (+1.13)
Stock to Watch: Orexigen Therapeutics Up 19.5% (OREX)
Comtex SmarTrend(R) - 2 hrs 25 mins ago
Orexigen Therapeutics (NASDAQ:OREX) is one of today's best performing low-priced stocks, up 19.5% to $4.60 on 1.1x average daily volume. Orexigen Therapeutics has traded 3.6 million shares thus far today, vs. average volume of 3.3 million shares per day. The stock has outperformed the Dow (19.5% to the Dow's 0.1%) and outperformed the S&P 500 (19.5% to the S&P's 0.3%) during today's trading.
OREX: 5.08 (+1.23)
Orexigen Therapeutics' (OREX) CEO Mike Narachi on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 10:51AM CST
OREX: 5.08 (+1.23)
Orexigen ups earnings by 161% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:16AM CST
OREX: 5.08 (+1.23)
Orexigen rises as weight loss drug review proceeds
AP - Mon Nov 10, 10:02AM CST
NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.
OREX: 5.08 (+1.23), VVUS: 3.23 (-0.10), ARNA: 4.34 (+0.08)
Orexigen Therapeutics (OREX) Stock Soars Today on Big Third Quarter Earnings Beat
at The Street - Mon Nov 10, 9:33AM CST
Orexigen Therapeutics (OREX) stock is skyrocketing this morning after the company posted higher than expected third quarter earnings.
OREX: 5.08 (+1.23)
Orexigen Beats The Street On Milestone Payments
Spencer Osborne - at Seeking Alpha - Mon Nov 10, 8:21AM CST
OREX: 5.08 (+1.23)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:14AM CST
PT: 1.63 (+0.11), GPRO: 76.08 (-2.98), OREX: 5.08 (+1.23), GOGO: 18.04 (+1.40), JRJC: 6.21 (+0.70), UEC: 1.87 (+0.15), ACHN: 12.54 (+2.43), ARQL: 1.16 (+0.10), CMCM: 20.50 (+0.30), IBIO: 1.24 (+0.08), DF: 16.31 (+1.89)
Orexigen Therapeutics (OREX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 7:25AM CST
OREX: 5.08 (+1.23)
Orexigen Therapeutics beats by $0.22, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:08AM CST
OREX: 5.08 (+1.23)
Orexigen Therapeutics Reports Results for the Third Quarter Ended September 30, 2014
PR Newswire - Mon Nov 10, 6:00AM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced results for the third quarter ended September 30, 2014.
OREX: 5.08 (+1.23)
Critical Alerts For Stratasys, Orexigen Therapeutics, YY, Workday and Hong Kong Television Network Released By InvestorsObserver
PR Newswire - Fri Nov 07, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for SSYS, OREX, YY, WDAY and HKTV.
OREX: 5.08 (+1.23), YY: 81.94 (+2.44), WDAY: 95.33 (+0.77), SSYS: 104.40 (+1.33), HKTV: 11.08 (+0.21)
Orexigen Therapeutics to Present at the Credit Suisse Healthcare Conference
PR Newswire - Thu Nov 06, 3:30PM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Credit Suisse Healthcare Conference in Phoenix. The presentation is scheduled for Tuesday, November 11th at 2:00 p.m. Mountain Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
OREX: 5.08 (+1.23)
Vivus Beats The Street On Milestone Payment For ED Drug
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:59AM CST
OREX: 5.08 (+1.23), VVUS: 3.23 (-0.10), ARNA: 4.34 (+0.08)
Orexigen Therapeutics to Host Third Quarter 2014 Financial Results Conference Call and Webcast
PR Newswire - Tue Nov 04, 3:15PM CST
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) will announce financial results for the third quarter 2014, on Monday, November 10, 2014 before markets open. The announcement will be followed by a live webcast and conference call at 8:30 a.m. Eastern time (5:30 a.m. Pacific time).
OREX: 5.07 (+1.22)
Orexigen's Contrave Has Modest Start
Spencer Osborne - at Seeking Alpha - Mon Nov 03, 12:30PM CST
OREX: 5.07 (+1.22), ARNA: 4.34 (+0.08)
Orexigen Announces Contrave® (naltrexone HCI and bupropion HCI extended release) Data Presentations at the ObesityWeek Meeting in Boston
PR Newswire - Fri Oct 31, 7:30AM CDT
Orexigen Therapeutics (NASDAQ: OREX) today announced three Contrave® (naltrexone HCI and bupropion HCI) and two disease awareness abstracts have been accepted for poster presentations at the upcoming ObesityWeek meeting. This meeting will be held November 2-7, 2014 in Boston at the Boston Convention and Exposition Center.
OREX: 5.07 (+1.22)
Orexigen Therapeutics Has Substantial Upside For Bull Investors
L&F Capital Management - at Seeking Alpha - Wed Oct 29, 7:27AM CDT
OREX: 5.07 (+1.22)
Arena Skimps on Data Disclosure From Weight-Loss Combo Study
at The Street - Wed Oct 29, 6:30AM CDT
Arena Pharmaceuticals provided very little useful information Tuesday night about the Belviq-phentermine weight-loss combination.
OREX: 5.07 (+1.22), ARNA: 4.34 (+0.08)
(0)
(0)